Drugs / SOLITOMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00635596 | Mar 2008 → Jan 2014 | cancer | Amgen Research (Munich) GmbH | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOLITOMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109264 ↗ |
| Known as | MT110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00635596 ↗ |
| Action | Deplete | “resulting in T-cell activation and a cytotoxic T-cell response against EpCAM+ cells” NCT00635596 ↗ |
| Modality | Protein / enzyme biologic | “MT110 is a bispecific (anti-EpCAM x anti-CD3) T-cell engager (BiTE)” NCT00635596 ↗ |
| Route | Intravenous | “continuous intravenous infusion over at least 28 days” NCT00635596 ↗ |
| Target | EPCAM | “Epithelial cell adhesion molecule cross-linking agent” CHEMBL2109264 ↗ |